Portal Biotech
@portalbiotech.bsky.social
Portal is revolutionising biosensing by bringing precise and universal nanopore-based proteomics and metabolomics solutions to the bench-top.
Portal Biotech Closes $35M Series A to Deliver First Full-Length Single-Molecule Protein Sequencer.
Breakthrough proteomics platform technology unlocks full-length protein sequencing and characterisation, accelerating drug development & diagnostics. tinyurl.com/5y9cjbej #proteomics #nanopore
Breakthrough proteomics platform technology unlocks full-length protein sequencing and characterisation, accelerating drug development & diagnostics. tinyurl.com/5y9cjbej #proteomics #nanopore
July 2, 2025 at 4:48 PM
Portal Biotech Closes $35M Series A to Deliver First Full-Length Single-Molecule Protein Sequencer.
Breakthrough proteomics platform technology unlocks full-length protein sequencing and characterisation, accelerating drug development & diagnostics. tinyurl.com/5y9cjbej #proteomics #nanopore
Breakthrough proteomics platform technology unlocks full-length protein sequencing and characterisation, accelerating drug development & diagnostics. tinyurl.com/5y9cjbej #proteomics #nanopore
Reposted by Portal Biotech
“The most important applications of protein sequencing will be the ones we have no idea about today”. Giovanni Maglia founder of Portal Biotech and keynote speaker of #RNGS25, during a chat with our flying reporter Sarah Geurs, Technology Expert at the VIB Tech Watch Core! prez.ly/Zmid
“The most important applications of protein sequencing will be the ones we have no idea about today”
Giovanni Maglia reflects on the future of next-generation proteomics and the challenges of de novo protein sequencing
prez.ly
April 2, 2025 at 12:00 PM
“The most important applications of protein sequencing will be the ones we have no idea about today”. Giovanni Maglia founder of Portal Biotech and keynote speaker of #RNGS25, during a chat with our flying reporter Sarah Geurs, Technology Expert at the VIB Tech Watch Core! prez.ly/Zmid